FDA's Biologics Naming Plan: Industry Wants 'Memorable' Suffixes
Executive Summary
Random letter-based suffixes will make it difficult for prescribers and patients to identify a given product, biopharma companies say, requesting that suffixes be derived from the license-holder's name; GPhA, Federal Trade Commission say FDA plan for distinguishable names will create confusion and uncertainty.
You may also be interested in...
FDA Biosimilars Acting Director Yim Is ‘Not A Great Fan’ Of Suffix-Based Naming Policy
Whether one accepts the view that concerns about active pharmacovigilance and the need to distinguish small molecules from biologics support the controversial nomenclature system is ‘a personal thing,’ Sarah Yim says.
US FDA Biosimilars Acting Director Yim ‘Not A Great Fan’ Of Suffix-Based Naming Policy
Whether one accepts the view that concerns about active pharmacovigilance and the need to distinguish small molecules from biologics support the controversial nomenclature system is ‘a personal thing,’ Sarah Yim says.
Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics
New US FDA draft guidance says that the agency will no longer change the proper names of originator biologics to include a four-letter suffix, although the agency will continue to attach suffixes to future approvals.